The impact of renal tubulointerstitial dysfunction on the early and long-term prognosis in chronic heart failure patients with preserved left ventricular ejection fraction
DOI:
https://doi.org/10.14739/2310-1237.2024.1.295166Keywords:
chronic heart failure, tubulointerstitial nephritis, hyponatremiaAbstract
Aim. To study the dependence of the early-term (1 year) and long-term (5 years) prognosis in patients with chronic heart failure (CHF) of ischemic origin with preserved left ventricular ejection fraction (LVEF) depending on renal tubulointerstitial functional disorders.
Materials and methods. The study involved 88 patients (men – 46.6 % (n = 41); women – 53.4 % (n = 47)) with CHF of ischemic origin, stage II A–B, stage II–IV according to NYHA, 67 % (n = 59) with sinus rhythm, and 33 % (n = 29) with atrial fibrillation. Patients with sinus rhythm and atrial fibrillation were matched in age (p = 0.483), height (p = 0.345), weight (p = 0.317), body surface area (p = 0.153). NGAL levels were analyzed using an ELISA kit (E-EL-H0096, Elabscience, USA). NAG levels were analyzed using an ELISA kit (SEA 069 Hu, Cloud-Clone Corp., USA). KIM-1 levels were analyzed using an ELISA kit (SEA 785 Hu, Cloud-Clone Corp., USA). Kaplan–Meier curves and Cox proportional hazards regression analysis were performed.
Results. No significant difference was found in the frequency of the cumulative endpoint during the first-year follow-up from the initial level of two markers of tubulointerstitial injury – KIM-1 (Log-Rank Test: p = 0.57529) and NAG (Log-Rank Test: p = 0.86001). According to the results of analysis of the Cox proportional hazards, only a tendency to increase in the risk factors of adverse events were observed in case of elevated KIM-1 (HR = 1.66; p = 0.5795) and NAG levels (HR = 1.1712; p = 0.8626) in this CHF patients’ cohort. Kaplan–Meier analysis revealed a probable (Log-Rank Test; p = 0.00141) increase in the frequency of the cumulative endpoint during the first year of follow-up in CHF patients with preserved LVEF due to increased serum NGAL level more than 168 ng/ml. According to the univariate model, an elevated serum NGAL level is associated with an increase in the relative risk by 4.2 times (95 % CI 1.78–16.89; p = 0.014). A reduced sodium level less than 142.5 mmol/l was associated with an increase in number of adverse cardiovascular events during the first-year follow- ups by 22 % (HR = 1.22, p = 0.029). After 5 years of follow-up, a decrease in sodium level less than 142.3 mmol/l is also characterized by a probable difference of the cumulative Kaplan–Meier’s curves (Cox–Mantel F-Test, p = 0.00287). According to the univariate model of Cox proportional hazards, the relative risk of adverse cardiovascular events in patients with CHF during the 5-year follow-up has a tendency to increase by 1.04 times (95 % CI 0.85–1.27; p = 0.72). Serum NGAL, a marker of renal tubulo-interstitial injury, doesn’t lose its properties as a powerful marker of an unfavorable long-term prognosis in patients with CHF with preserved LVEF (HR = 5.96; 95 % CI 1.17–30.50; p = 0.032).
Conclusions. The most powerful factors of the early (1-year) prognosis of adverse cardiovascular events in CHF patients with preserved left ventricular ejection fraction are the marker of tubulointerstitial injury, serum NGAL over 168 ng/ml, as well as the marker of tubulointerstitial dysfunction – the serum sodium level less than 142.5 mmol/l. The electrolyte imbalance, decreased sodium level less than 142.3 mmol/l, remains a powerful marker of an unfavorable long-term 5-year prognosis in CHF patients with preserved left ventricular ejection fraction, meanwhile serum NGAL, a marker of renal tubulointerstitial injury, besides doesn’t lose its prognostic value (HR = 5.96; 95 % CI 1.17–30.50; p = 0.032), but also is independent from the parameters of the age (p = 0.409) and gender (p = 0.397) in such patients.
References
Lysenko VA, Syvolap VV, Potapenko MS. The relationship between systolic function and serum NGAL levels in patients with chronic heart failure of ischemic origin. Zaporozhye Medical Journal, 2021;23(2):184-8. doi: https://doi.org/10.14739/2310-1210.2021.2.223741
Miyamori D, Tanaka M, Sato T, Endo K, Mori K, Mikami T, et al. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease. J Am Heart Assoc. 2023;12(14):e030269. doi: https://doi.org/10.1161/JAHA.123.030269
Jana S, Mitra P, Roy S. Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review. Diseases. 2022;11(1):8. doi: https://doi.org/10.3390/diseases11010008
Brankovic M, Akkerhuis KM, Hoorn EJ, van Boven N, van den Berge JC, Constantinescu A, et al. Renal tubular damage and worsening renal function in chronic heart failure: Clinical determinants and relation to prognosis (Bio-SHiFT study). Clin Cardiol. 2020;43(6):630-8. doi: https://doi.org/10.1002/clc.23359
Buliga-Finis ON, Ouatu A, Badescu MC, Dima N, Tanase DM, Richter P, et al. Beyond the Cardiorenal Syndrome: Pathophysiological Approaches and Biomarkers for Renal and Cardiac Crosstalk. Diagnostics (Basel). 2022;12(4):773. doi: https://doi.org/10.3390/diagnostics12040773
Romejko K, Markowska M, Niemczyk S. The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL). Int J Mol Sci. 2023;24(13):10470. doi: https://doi.org/10.3390/ijms241310470
Chong JJH, Prince RL, Thompson PL, Thavapalachandran S, Ooi E, Devine A, et al. Association Between Plasma Neutrophil Gelatinase-Associated Lipocalin and Cardiac Disease Hospitalizations and Deaths in Older Women. J Am Heart Assoc. 2019;8(1):e011028. doi: https://doi.org/10.1161/JAHA.118.011028
Lysenko VA, Syvolap VV. Independent predictors of adverse cardiovascular events in patients with CHF of ischemic origin. East European Scientific Journal. 2021;69(5):33-7. doi: https://doi.org/10.31618/ESSA.2782-1994.2021.1.69.42
Christopoulou E, Liamis G, Naka K, Touloupis P, Gkartzonikas I, Florentin M. Hyponatremia in Patients with Heart Failure beyond the Neurohormonal Activation Associated with Reduced Cardiac Output: A Holistic Approach. Cardiology. 2022;147(5-6):507-20. doi: https://doi.org/10.1159/000526912
Yeoh SE, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial. JACC Heart Fail. 2022;10(5):306-18. doi: https://doi.org/10.1016/j.jchf.2022.01.019
Peng S, Peng J, Yang L, Ke W. Relationship between serum sodium levels and all-cause mortality in congestive heart failure patients: A retrospective cohort study based on the Mimic-III database. Front Cardiovasc Med. 2023;9:1082845. doi: https://doi.org/10.3389/fcvm.2022.1082845
Voronkov LH, Amosova KM, Dziak HV, Zharinov OY, Kovalenko VM, Korkushko OV, et al. Rekomendatsii Asotsiatsii k ardiolohiv Ukrainy z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti (2017) [Guidelines of the Ukrainian Association of Cardiology for the Diagnosis and Treatment of Chronic Heart Failure (2017)]. Sertseva nedostatnist ta komorbidni stany. 2017;1(Suppl 1):1-66. Ukrainian.
Josa-Laorden C, Rubio-Gracia J, Sánchez-Marteles M, Torcal P, Garcés-Horna V, Sola-Martínez A, et al. Elevated urinary kidney injury molecule 1 at discharge strongly predicts early mortality following an episode of acute decompensated heart failure. Pol Arch Intern Med. 2022;132(9):16284. doi: https://doi.org/10.20452/pamw.16284
Haredasht FN, Vanhoutte L, Vens C, Pottel H, Viaene L, De Corte W. Validated risk prediction models for outcomes of acute kidney injury: a systematic review. BMC Nephrol. 2023;24(1):133. doi: https://doi.org/10.1186/s12882-023-03150-0
Łagosz P, Biegus J, Urban S, Zymliński R. Renal Assessment in Acute Cardiorenal Syndrome. Biomolecules. 2023;13(2):239. doi: https://doi.org/10.3390/biom13020239
Zdanowicz A, Urban S, Ponikowska B, Iwanek G, Zymliński R, Ponikowski P, et al. Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure. J Pers Med. 2022;12(6):898. doi: https://doi.org/10.3390/jpm12060898
Atici A, Emet S, Toprak ID, Cakmak R, Akarsu M, Tukek T. The role of kidney injury molecule-1 in predicting cardiorenal syndrome type 1 after diuretic treatment. Arch Med Sci Atheroscler Dis. 2019;4:e208-14. doi: https://doi.org/10.5114/amsad.2019.87305
Chung EY, Trinh K, Li J, Hahn SH, Endre ZH, Rogers NM, et al. Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics. Front Cardiovasc Med. 2022;9:868658. doi: https://doi.org/10.3389/fcvm.2022.868658
Sheshadri A, Lai M, Hsu FC, Bauer SR, Chen SH, Tse W, et al. Structured Moderate Exercise and Biomarkers of Kidney Health in Sedentary Older Adults: The Lifestyle Interventions and Independence for Elders Randomized Clinical Trial. Kidney Med. 2023;5(11):100721. doi: https://doi.org/10.1016/j.xkme.2023.100721
Fu K, Hu Y, Zhang H, Wang C, Lin Z, Lu H, et al. Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment. Front Cardiovasc Med. 2021;8:760152. doi: https://doi.org/10.3389/fcvm.2021.760152
Kenneally LF, Lorenzo M, Romero-González G, Cobo M, Núñez G, Górriz JL, et al. Kidney function changes in acute heart failure: a practical approach to interpretation and management. Clin Kidney J. 2023;16(10):1587-99. doi: https://doi.org/10.1093/ckj/sfad031
Otaki Y, Watanabe T, Shimizu M, Tachibana S, Sato J, Kobayashi Y, et al. Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease. ESC Heart Fail. 2023;10(4):2458-68. doi: https://doi.org/10.1002/ehf2.14378
Chen X, Li X, Zhang K, Lian K, Zhang W, Song Y, et al. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances. Clin Exp Nephrol. 2024;28(2):125-35. doi: https://doi.org/10.1007/s10157-023-02413-2
Ogobuiro I, Tuma F. Physiology, Renal. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Available from: https://www.ncbi.nlm.nih.gov/books/NBK538339/
Shah V, Jahan N. Prognostic Significance of Hyponatremia in ST-elevation Myocardial Infarction/Heart Failure Patients. Cureus. 2019;11(9):e5673. doi: https://doi.org/10.7759/cureus.5673
Su Y, Ma M, Zhang H, Pan X, Zhang X, Zhang F, et al. Prognostic value of serum hyponatremia for outcomes in patients with heart failure with preserved ejection fraction: An observational cohort study. Exp Ther Med. 2020;20(5):101. doi: https://doi.org/10.3892/etm.2020.9231
Rao J, Ma Y, Long J, Tu Y, Guo Z. The combined impact of hyponatremia and hematocrit on the risk for 90-day readmission and death in patients with heart failure: dilutional hyponatremia versus depletional hyponatremia. Ann Saudi Med. 2023;43(1):17-24. doi: https://doi.org/10.5144/0256-4947.2023.17
Sarastri Y, Zebua JI, Lubis PN, Zahra F, Lubis AC. Admission hyponatraemia as heart failure events predictor in patients with acute heart failure. ESC Heart Fail. 2023;10(5):2966-72. doi: https://doi.org/10.1002/ehf2.14472
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).